Short Human Opsin Promoter for Rod-Specific Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors for retinal diseases, such as retinitis pigmentosa, lack promoters that efficiently and selectively drive transgene expression in rod photoreceptors with minimal off-target expression in cone photoreceptors or retinal pigment epithelium, and are limited by carrying capacity for large transgenes.
Innovation Solution
Development of a short enhanced human opsin promoter, hOp181opt, optimized for rod-specific expression, integrated into a recombinant adeno-associated viral vector, which includes an enhancer element, allowing efficient and targeted delivery of transgenes like CNGB1 to rod cells with reduced off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional promoters (human rhodopsin kinase promoter, human opsin promoter, mouse opsin promoter, IRBP) are used for rod-specific expression, then rod photoreceptor expression is achieved, but the promoter length exceeds vector carrying capacity limits or expression efficiency/selectivity is insufficient
Solution Approach 1:
The patent extracts and isolates the minimal functional core of the human opsin promoter (positions -181 to +1 of the transcription start site) that is sufficient for rod-specific expression. This truncated promoter fragment (181 base pairs) maintains the critical transcription factor binding sites while removing unnecessary flanking sequences, thereby reducing length below the 4.9 Kb vector carrying capacity limit while preserving rod-selective expression functionality.
Solution Approach 2:
The patent modifies the promoter by changing the parameter of length through precise truncation to 181 base pairs. This parameter change enables the promoter to fit within the carrying capacity constraints of the viral vector while the expression functionality is maintained through conservation of the essential transcription factor binding sites (CRX, NRL, and other rod-specific elements) within this shortened sequence.
2Quantity of substance
If promoters are shortened to accommodate large transgenes in viral vectors, then vector carrying capacity is improved, but transgene expression efficiency may be reduced
Solution Approach 1:
The patent applies local quality by concentrating all essential transcriptional control elements within the 181 base pair promoter sequence. The critical transcription factor binding sites (including CRX, NRL, and other rod-specific elements) are locally optimized and densely packed within this short sequence, ensuring that despite the overall length reduction, the promoter maintains high transcriptional activity and rod-specific expression efficiency when driving large transgenes.
Data Source
AI summary
The present disclosure provides short enhanced human opsin promoters for rod-specific expression that satisfy a need in the art for promoters that are able to control transgene expression both efficiently and selectively in rod cells, with little to no off-target expression in other photoreceptor cells. The disclosure provides vector constructs comprising transgenes operably controlled by this enhanced human opsin promoter that may be delivered and targeted with high specificity to rod cells. The disclosure also provides compositions comprising these vector constructs and methods for administration of these compositions to subjects in need thereof.